Hormone therapy and ovarian cancer

Affiliations

¹ Menopause Unit, Hôpital Paule de Viguier, CHU de Toulouse, Toulouse, France. Electronic address: tremollieres.f@chu-toulouse.fr.
² Service de Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU de Nantes, Nantes, France.
³ Unité de Gynécologie endocrinienne, Université Paris Descartes, Hôpital Port Royal Cochin, Paris, France.

Comment

Florence Trémollieres et al. Lancet. 2015.

. 2015 Sep 12;386(9998):1038.

doi: 10.1016/S0140-6736(15)00139-7.

¹ Menopause Unit, Hôpital Paule de Viguier, CHU de Toulouse, Toulouse, France. Electronic address: tremollieres.f@chu-toulouse.fr.
² Service de Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU de Nantes, Nantes, France.
³ Unité de Gynécologie endocrinienne, Université Paris Descartes, Hôpital Port Royal Cochin, Paris, France.

No abstract available

Comment in

Hormone therapy and ovarian cancer - Authors' reply.
Beral V, Hermon C, Peto R, Reeves G; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, et al. Lancet. 2015 Sep 12;386(9998):1038-9. doi: 10.1016/S0140-6736(15)00140-3. Lancet. 2015. PMID: 26382993 No abstract available.

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
Collaborative Group On Epidemiological Studies Of Ovarian Cancer; Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, et al. Lancet. 2015 May 9;385(9980):1835-42. doi: 10.1016/S0140-6736(14)61687-1. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684585 Free PMC article.